Lv62
2050 积分 2024-06-18 加入
Cyclophilin A-Deficient Mice Are Resistant to Immunosuppression by Cyclosporine
6小时前
已完结
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
10天前
已完结
Tumor-draining lymph nodes: At the crossroads of metastasis and immunity
11天前
已完结
STX-478, RLY-2608, and LOXO-783: third-generation PIK3CA mutant-selective allosteric inhibitors
17天前
已关闭
Precision Oncology: 2025 in Review
19天前
已完结
Recent Advance of KRAS-G12C Inhibitors for Cancer Therapy
24天前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
1个月前
已完结
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
1个月前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
2个月前
已完结
Discovery and Characterization of RP03707: A Highly Potent and Selective KRASG12D PROTAC
2个月前
已完结
皖公网安备34019202002308
